TB/FLU-05E is a mucosal TB vaccine candidate based on recombinant attenuated influenza vector (Flu/THSP) co-expressing truncated NS1 protein NS1(1–124) and a full-length TB10.4 and HspX proteins of M.tb within an NS1 protein open reading frame. Vaccine formulation: Liquid nasal spray.
Sponsor / Lead Developer: Smorodintsev Research Institute of Influenza
Federal State Unitary Enterprise “Scientific and Production Association for Immunological Preparations “Microgen” of the Ministry of Health of the Russian Federation
Primary Indication: Prevention of Mtb infection or sustained infection
Other Indication(s): Prevention of TB recurrence
Target Population(s): Adolescents, Adults, and Children
Target Route of Administration: Intranasal
|Clinical Trial Phase||Phase 1|
|Sponsor||Research Institute of Influenza|
|Primary endpoint(s) for this clinical trial||Safety|
|Target population(s) for clinical trial||Adults|
- Enhancement of the Local CD8+ T-Cellular Immune Response to Mycobacterium tuberculosis in BCG-Primed Mice after Intranasal Administration of Influenza Vector Vaccine Carrying TB10.4 and HspX Antigens. Vaccines (Basel). (2021).
- Mucosal Influenza Vector Vaccine Carrying TB10.4 and HspX Antigens Provides Protection against Mycobacterium tuberculosis in Mice and Guinea Pigs. Vaccines (Basel). (2021)